From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

Welcome to Journal Watch. The content you requested requires sign in with a username and password.

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: The Bad Actor in the Group

In this aggressive lymphoma subtype, combined chemotherapy and rituximab treatment was associated with better outcomes.

Sign In

Forgot your password?

If you do not use cookies, sign in here.

Don't yet have a username or password?

Register now for

Journal Watch e-mail alerts and unlimited online access to articles 6 months after publication. register

Subscribe now for

Full, immediate online access to all Journal Watch content and services. subscribe

Already a subscriber? Activate your subscription to receive full online access.

Get full site access with a 7-day site pass for $19

Copyright © 2008. Massachusetts Medical Society. All rights reserved.